SQZ Biotech Closes $65 Million Series D Financing
Summary
The company also announced the expansion of its cellular vaccine platform, currently in trial for oncology, into infectious diseases, and development of a point-of-care system to potentially generate patient product directly at treatment centers. Coupled with our rapid central manufacturing and investment in developing a new point-of-care system, we believe SQZ’s differentiated approach to treating disease could provide meaningful benefit to many patients,” commented Armon Sharei, PhD, chief executive officer of SQZ Biotech. The financing will support the advancement of SQZ’s current pipeline of multi-functional cell therapies, designed to direct specific immune responses, and its expansion into infectious diseases. “We remain in a strong position to continue to execute on our goals and achieve milestones across the SQZ portfolio.” SQZ’s announcement included the Company’s expansion of its cellular vaccine capabilities into infectious diseases. Through the generation of pathogen targeting CD8 T cell responses, SQZ’s cell-based vaccines could potentially address numerous chronic infections and novel viruses in both prophylactic and therapeutic patient settings.